216 related articles for article (PubMed ID: 2167952)
1. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
[TBL] [Abstract][Full Text] [Related]
2. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Perez CA
Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):7-12. PubMed ID: 1847128
[TBL] [Abstract][Full Text] [Related]
3. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
[TBL] [Abstract][Full Text] [Related]
4. Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08.
Cox JD; Pajak TF; Herskovic A; Urtasun R; Podolsky WJ; Seydel HG
Am J Clin Oncol; 1991 Aug; 14(4):280-4. PubMed ID: 1650526
[TBL] [Abstract][Full Text] [Related]
5. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
6. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
7. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Sause W; Kolesar P; Taylor S IV; Johnson D; Livingston R; Komaki R; Emami B; Curran W; Byhardt R; Dar AR; Turrisi A
Chest; 2000 Feb; 117(2):358-64. PubMed ID: 10669675
[TBL] [Abstract][Full Text] [Related]
8. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.
Cox JD; Pajak TF; Asbell S; Russell AH; Pederson J; Byhardt RW; Emami B; Roach M
Int J Radiat Oncol Biol Phys; 1993 Oct; 27(3):493-8. PubMed ID: 8226140
[TBL] [Abstract][Full Text] [Related]
9. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
10. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11.
Curran WJ; Cox JD; Azarnia N; Byhardt RW; Shin KH; Emani B; Phillips TL; Selim H; Herskovic A; Mohiuddin M
Cancer; 1991 Aug; 68(3):509-16. PubMed ID: 1648432
[TBL] [Abstract][Full Text] [Related]
12. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.
Jeremic B; Shibamoto Y; Acimovic L; Djuric L
J Clin Oncol; 1995 Feb; 13(2):452-8. PubMed ID: 7844608
[TBL] [Abstract][Full Text] [Related]
14. Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies.
Cox JD; Sause WT; Byhardt RW; Komaki R; Perez CA; Pajak TF
Lung Cancer; 1994 Mar; 10 Suppl 1():S161-6. PubMed ID: 8087506
[TBL] [Abstract][Full Text] [Related]
15. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07.
Byhardt RW; Pajak TF; Emami B; Herskovic A; Doggett RS; Olsen LA
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):459-68. PubMed ID: 8390420
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
18. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.
Cox JD; Pajak TF; Marcial VA; Hanks GE; Mohiuddin M; Fu KK; Byhardt RW; Rubin P
Int J Radiat Oncol Biol Phys; 1990 Mar; 18(3):515-21. PubMed ID: 2180866
[TBL] [Abstract][Full Text] [Related]
19. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]